<DOC>
	<DOCNO>NCT02279537</DOCNO>
	<brief_summary>The purpose study collect real-life data patient wet age relate macular degeneration ( AMD ) treatment Eylea initiate</brief_summary>
	<brief_title>Real Life Aflibercept In FraNce : oBservatiOnnal Study Wet AMD</brief_title>
	<detailed_description>The study retrospective prospective collect local real life data patient routine treatment . The observation period start January 2014 . Patients receive 1st injection Eylea January 2014 enrol . Patients follow period 48 month longer possible</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Patient diagnosis wet AMD enrol decision treatment Aflibercept ( Eylea ) make Patient 1st injection Eylea 01 January 2014 30 April 2015 enrol Prior/current treatment antiVEGF intravitreal injection macular laser ( laser and/or visudyne/PDT ) fellow eye allow Man woman age 18 year Patient give appropriate information study objectives procedure give his/her write , informed consent ; Patient another retinal disease : diabetic retinopathy , diabetic macular oedema ( DME ) , myopic choroidal neovascularization , retinal vein occlusion ( RVO ) , central serous chorioretinopathy ( CSC ) , angioid streak Patient meet local indication criterion Eylea treatment.Contraindications list Summary Product Characteristics ( SmPC ) must take account Patient previously treat macular laser ( laser and/or visudyne/PDT ) antiVEGF intravitreal injection study eye Patient take part interventional study time enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Wet age-related macular Degeneration ( Wet-AMD )</keyword>
	<keyword>Na√Øve patient</keyword>
	<keyword>Real life</keyword>
	<keyword>Aflibercept</keyword>
</DOC>